Results 101 to 110 of about 27,191 (241)

Oral Lesions Developed in Post‐Hematopoietic Stem Cell Transplant Patients and the Role of Cryogun Cryotherapy

Clinical and Experimental Dental Research, Volume 12, Issue 3, June 2026.
ABSTRACT Objective To investigate the development of oral premalignant and malignant lesions as a major long‐term complication following hematopoietic stem cell transplantation. Methods This single‐center retrospective study identified 17 patients who developed 26 pathology‐confirmed oral premalignant and malignant lesions after hematopoietic stem cell
Pei Hsuan Lu, Kelly Yi Ping Liu, Samson P. Ng, Catherine F. Poh   +3 more
wiley   +1 more source

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies

Haematologica, 2016
Bone marrow fibrosis is a central pathological feature and World Health Organization major diagnostic criterion of myelofibrosis. Although bone marrow fibrosis is seen in a variety of malignant and non-malignant disease states, the deposition of ...
Abdallah Abou Zahr, Mohamed E. Salama, Nicole Carreau, Douglas Tremblay, Srdan Verstovsek, Ruben Mesa, Ronald Hoffman, John Mascarenhas   +7 more
doaj   +1 more source

What's Your Diagnosis? A Case of Extreme Thrombocytosis in a Dog

Veterinary Clinical Pathology, EarlyView.
Stephanie F. Anderson, King Long Hannah Lee, Megan Dietz, Sarah Guess, Laura White, Mara S. Varvil   +5 more
wiley   +1 more source

Ruxolitinib for Myelofibrosis [PDF]

New England Journal of Medicine, 2012
Steffen, Koschmieder, Adriane, Koppelle, Hans, Seifert   +2 more
openaire   +4 more sources

This Is Not a Myeloproliferative Neoplasm…

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
Stephanie Juané Kennedy
wiley   +1 more source

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor

, 2017
Palma Manduzio Department of Haematology and Oncology, Haematology With BMT, IRCCS, Casa Sollievo della Sofferenza, Foggia, Italy Abstract: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm classified according to the 2016 revision of World ...
Manduzio P
core  

Practical management of myelofibrosis with ruxolitinib

, 2015
Treatment for the majority of patients with myelofibrosis is primarily based on symptom control as curative allogeneic stem cell transplantation is typically offered only to younger patients, especially those with poor prognosis disease.
Marlton, P., Ritchie, D, Stevenson, W., Dunlop, L.C., Ritchie, D., Ross, David M., Bird, Robert, Durrant, S, Ho, PJ, Tam, C., Ross, D. M., Bird, R, Ho, Joy, Ross, DM, Ross, D.M., Marlton, Paula V., Stevenson, W, Dunlop, L. C., Dunlop, LC, Ritchie, David, Dunlop, Lindsay C. (R18423), Tam, Constantine, Tam, C, Bird, R., Ho, P., Ho, P.J., Marlton, P, Bird, Robert J., Durrant, S., Durrant, Simon   +29 more
core   +1 more source

Ruxolitinib for the treatment of myelofibrosis: its clinical potential

, 2012
Alen Ostojic1, Radovan Vrhovac1, Srdan Verstovsek21Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, Zagreb, Croatia; 2Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX ...
Vrhovac R, Verstovsek S, Ostojic A
core  

Clinical Images: Thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly syndrome presenting as bilateral adrenal hemorrhage

ACR Open Rheumatology, Volume 8, Issue 6, June 2026.
Masaki Itagane, Mitsuyo Kinjo
wiley   +1 more source

Genetic Variants of BMI1 (rs1042059 and rs11591377) and Their Potential Role in Leukemia Susceptibility: A Narrative Review

Health Science Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background and Aims Leukemia is a heterogeneous group of hematologic malignancies influenced by both genetic and environmental factors. The B‐cell‐specific Moloney murine leukemia virus integration site 1 (BMI1) gene, a key regulator of hematopoietic stem cell self‐renewal and oncogenesis, has been implicated in leukemia pathogenesis.
Mojtaba Aghaei, Niloufar Afrough, Mohammad Ali Jalali Far   +2 more
wiley   +1 more source